Company profile
Encoded Therapeutics, Inc.
Privately held: no public share price (San Francisco gene-therapy company (Dravet syndrome), $239M raised across 5 rounds from VC investors (Menlo Ventures, RTW Investments, ARCH Venture Partners, Venrock, etc.). No evidence of an IPO -- privately held. Sources: https://clinicaltrials.gov/study/NCT05419492 ; https://www.prnewswire.com/news-releases/encoded-therapeutics-inc-announces-104-million-series-c-financing-to-advance-lead-gene-therapy-program-in-dravet-syndrome-and-unveils-its-precision-gene-therapy-platform-300874993.html ; https://tracxn.com/d/companies/encoded/__oqnNzf4ETpKdQcW6WSlQr7q6WJdnfMcwyGWyZQVgBg4 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | SCN1A (transcriptional upregulation)Gene therapy / editing | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.